Until now, the eligibility of HNSCC patients for anti-PD-1 therapy is determined by the combined positive score (CPS), which includes the total number of PD-L1+ cells (both tumor and immune cells). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.